Newly approved anti-amyloid therapies have spurred hope for patients and caregivers affected by Alzheimer's disease, but access to these drugs could be stymied by a lack of convenient and available beta-amyloid testing options.

he latest report on clinical trials in the Alzheimer’s drug development pipeline points to the growing potential of anti-amyloid monoclonal antibodies for treating the brain-robbing condition. Anti-inflammatory agents comprise the single largest therapeutic category with 25 drugs, but astoundingly no two are aimed at the same target, according to lead author Jeffrey Cummings, M.D., research professor in the school of integrated health sciences at the University of Nevada, Las Vegas, and director of its Chambers-Grundy Center for Transformative Neuroscience.

Up to 50 percent of people in the U.S. with Alzheimer’s receive an imprecise or inaccurate diagnosis of their cognitive condition. The tools typically used to detect the disease, like a PET scan, can cost thousands of dollars and are generally only available in places with large medical institutions. And African Americans are 35 percent less likely to be diagnosed than their White counterparts.

More than 6.7 million individuals in the U.S. have Alzheimer’s disease, and that number is growing rapidly. Each day that passes without effective treatments brings tragic consequences for patients and their loved ones. As the debate over coverage for new Alzheimer’s drugs continues,  Dr. Jeffrey Cummings of the University of Nevada, Las Vegas, joined us to discuss the challenging path that led to these medicines, the state of the science now, and hope for the future.

KNX In Depth's Charles Feldman and Rob Archer discuss a new study that looks into Alzheimer's research and drugs. It sounds optimistic when it comes to the future of treating the disease.

More than 6 million Americans are living with Alzheimer's disease, a staggering number that's expected to double within the next 30 years.

Could changing your diet play a role in slowing or even preventing the development of dementia? We're one step closer to finding out, thanks to a new UNLV study that bolsters the long-suspected link between gut health and Alzheimer's disease.

Lighthouse Pharmaceuticals, a clinical-stage pharmaceutical company developing therapeutics to alter the course of dementia and other degenerative diseases, announced completion of a Pre-investigational New Drug meeting with the Food and Drug Administration related to the planned Phase 2b clinical study of LHP588 and the formation of its Clinical Advisory Board (CAB). The CAB includes six members with diverse backgrounds and expertise in dementia, Alzheimer’s disease, inflammation, neurodegenerative disorders, and drug development.